clinicallaser.seCrawled Nov 19, 2026
CLS Americas partnered with Genesis Research to conduct a Phase I clinical study on laser ablation for prostate cancer.
CLS explains how its FDA-cleared laser ablation system for neurosurgery works.
CLS began with pipeline research and now conducts clinical studies to develop new therapies for serious diseases, including cancer.
CLS develops and commercializes minimally invasive therapy systems that use heat from focused laser light for image-guided tissue ablation.
Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.
CLS’s CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik discuss the design of TRANBERG Thermal Therapy Systems for precise and safe focal therapy of soft tissue, such as the prostate gland, and outline current research efforts.
CLS and Skåne University Hospital will evaluate laser ablation for glioblastoma patients in a clinical trial.
CLS has entered an agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on a commercial evaluation of its second-generation TRANBERG Thermal Therapy System with Thermoguide Workstation in MR-guided stereotactic focal laser ablation of localized prostate cancer.
CLS participated in the 2022 European Conference on Interventional Oncology in Vienna, Austria.
Radboud University Medical Center approved a trial to evaluate magnetic resonance-guided laser ablation for localized prostate cancer using the TRANBERG Thermal Therapy System.
SVT’s local news featured Skåne University Hospital’s use of CLS systems for brain tumor operations inside an MRI.
CLS seeks candidates to join its team focused on precise cancer treatment.
Joel Hix, Director of Clinical Operations at CLS Americas, has over 15 years of senior management experience in operations, sales, marketing, and service for medical device manufacturers including Boston Scientific and Healthtronics.
CLS’s board has experience in the medtech industry, commercialization of medtech products, oncology, and financial markets. Peter Max, born in 1961, has served as Chairman of the Board since 2024.
CLS’s management team has experience in product and business development for medtech products, cancer care, regulatory work, and international marketing. Dan J. Mogren has served as CEO since 2022.
CLS develops precise treatment tools for laser ablation of diseased tissue.
Professor Karl-Göran Tranberg’s research into laser-generated thermal ablation of cancer tumors revealed the immune system’s ability to target cancer cells throughout the body, known as the abscopal effect.
CLS’s journey began in 2006 with Professor Karl-Göran Tranberg’s discovery that laser beams could destroy cancer and activate the immune system. In 2023, the ClearPoint Prism Neuro Laser Therapy System launched for minimally invasive brain surgery.
CLS has offices in Europe, North America, and Asia, with its head office in Lund, Sweden.
CLS provides tools for precise tissue ablation using laser-generated heat, targeting advancements in cancer care and neurosurgery.
Clinical Laserthermia Systems AB is a public company based in Skåne County, Lund, developing, manufacturing, importing, and trading medical equipment.
Villkor för teckningsoptioner TO 5_Terms for warrants of series TO 5 (SE_ENG)